Home Cart 0 Sign in  

[ CAS No. 313516-66-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 313516-66-4
Chemical Structure| 313516-66-4
Structure of 313516-66-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 313516-66-4 ]

Related Doc. of [ 313516-66-4 ]

Alternatived Products of [ 313516-66-4 ]

Product Details of [ 313516-66-4 ]

CAS No. :313516-66-4 MDL No. :MFCD00121849
Formula : C12H8ClN3O3 Boiling Point : -
Linear Structure Formula :- InChI Key :FRPJSHKMZHWJBE-UHFFFAOYSA-N
M.W : 277.66 Pubchem ID :2777391
Synonyms :
Chemical Name :2-Chloro-5-nitro-N-(pyridin-4-yl)benzamide

Calculated chemistry of [ 313516-66-4 ]

Physicochemical Properties

Num. heavy atoms : 19
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.0
Num. rotatable bonds : 4
Num. H-bond acceptors : 4.0
Num. H-bond donors : 1.0
Molar Refractivity : 72.28
TPSA : 87.81 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.09 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.41
Log Po/w (XLOGP3) : 1.27
Log Po/w (WLOGP) : 2.7
Log Po/w (MLOGP) : 0.99
Log Po/w (SILICOS-IT) : 0.51
Consensus Log Po/w : 1.38

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.56
Solubility : 0.756 mg/ml ; 0.00272 mol/l
Class : Soluble
Log S (Ali) : -2.71
Solubility : 0.538 mg/ml ; 0.00194 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.54
Solubility : 0.00806 mg/ml ; 0.000029 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.0

Safety of [ 313516-66-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P305+P351+P338 UN#:N/A
Hazard Statements:H302-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 313516-66-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 313516-66-4 ]
  • Downstream synthetic route of [ 313516-66-4 ]

[ 313516-66-4 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 504-24-5 ]
  • [ 2516-96-3 ]
  • [ 313516-66-4 ]
YieldReaction ConditionsOperation in experiment
58%
Stage #1: With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 2 h;
Stage #2: With triethylamine In dichloromethane at 20℃; for 16 h;
To a solution of 2-chloro-5-nitrobenzoic acid (0.500 g, 2.48 mmol) in dichloromethane (8.3 mL) was added oxalyl chloride (0.239 mL, 2.73 mmol) slowly, followed by /V,N-dimethylformamide ( 1 drop). The reaction was stirred at room temperature for 2 hours. To the solution was added triethylamine (0.691 mL, 4.96 mmol) followed by pyridin-4-amine (0.467 g, 4.96 mmol) in dichloromethane ( 1 mL). The reaction was allowed to stir at room temperature for 16 hours. Purification by flash column chromatography using 0-100percent ethyl acetate/hexanes as eluent provided the title compound as a tan solid (0.401 g, 58percent) : ' H NMR (400 MHz, DMSO-de) δ 11.10 (s, 1H), 8.64 - 8.45 (m, 3H), 8.37 (dd, J = 8.9, 2.8 Hz, 1 H), 7.92 (d, J = 8.8 Hz, 1H), 7.73 - 7.61 (m, 2H) ; 13C NMR ( 101 MHz, DMSO-de) δ 163.67, 150.56, 146.14, 145.04, 136.95, 131.40, 126.06, 124.00, 113.68 ; ESIMS m/z 278 ( [M + H ]+ ).
Reference: [1] Patent: WO2016/168059, 2016, A1, . Location in patent: Page/Page column 160
  • 2
  • [ 504-24-5 ]
  • [ 25784-91-2 ]
  • [ 313516-66-4 ]
Reference: [1] Patent: US2003/134859, 2003, A1,
[2] Patent: US2003/134859, 2003, A1,
Same Skeleton Products
Historical Records